Form 4: Cormorant Asset Management Increases Stake in Corbus Pharmaceuticals Holdings

Cormorant Asset Management, LP, along with related entities and Bihua Chen, reports the acquisition of additional shares of Corbus Pharmaceuticals Holdings, Inc. common stock through a series of open market transactions.

Summary

• Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, and Bihua Chen have reported changes in their beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. (CRBP) common stock.
• Between March 7, 2024, and March 8, 2024, the Master Fund purchased shares of common stock in a series of open market transactions.
• The purchases were made at varying prices, ranging from $37.53 to $46.00 per share.
• As a result of these transactions, the total number of shares beneficially owned by the reporting persons has increased to 2,025,000.
• The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased stake suggests confidence, but the disclaimer of beneficial ownership beyond pecuniary interest tempers the enthusiasm.

Positives

• Cormorant Asset Management's increased investment in Corbus Pharmaceuticals could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing reflects investment activity in the pharmaceutical sector, where investment firms like Cormorant Asset Management actively manage their portfolios based on their assessment of company performance and future potential.

Stakeholder Impact

• The increased stake by Cormorant Asset Management could positively influence shareholder confidence.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates